ArticleNature communications2026
Ultra-fast self-gelling self-expanding self-propelling high-adhesion procoagulant hemostatic powder for non-compressible hemorrhage hemostasis in pigs.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Non-compressible hemorrhage remains the chief cause of battlefield mortality and civilian trauma death. Here, we propose a hemostatic strategy based on ultrafast self-gelling self-expanding powder of polyacrylic acid (PAA), polyethyleneimine (PEI) and foaming agent, which achieves non-compressible hemorrhage hemostasis through the multiple synergistic effects of expansion plugging, self-gelling adhesion and activating the coagulation factors. The hemostatic powder integrates rapid physical crosslinking with spontaneous gas foaming, exhibits a fast gelation rate, high expansion ratio, strong tissue adhesion, and activation of red blood cells, platelets, and fibrin. The optimized formulation (PP/PT5-TXA30) achieves superior hemostatic performance compared to commercial powders in rat liver volumetric defect, femoral artery and vein transection, as well as complete transection of the subclavian artery and vein in rabbits. Notably, in a lethal porcine model of complete subclavian artery and vein transection, PP/PT5-TXA30 achieves superior performance of non-compressible hemorrhage compared to gauze and XStat™. Additionally, PP/PT5-TXA30 accelerates full-thickness skin wound healing. This work demonstrates a strategy based on ultra-fast self-gelling and self-expanding mechanisms for developing hemostatic materials for non-compressible hemorrhage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.